Impact of allergic rhinitis on the day-to-day lives of children : Insights from an Australian cross-sectional study by Bosnic-Anticevich, Sinthia et al.
1Bosnic- Anticevich S, et al. BMJ Open 2020;10:e038870. doi:10.1136/bmjopen-2020-038870
Open access 
Impact of allergic rhinitis on the day- to- 
day lives of children: insights from an 
Australian cross- sectional study
Sinthia Bosnic- Anticevich   ,1 Peter Smith,2 Michael Abramson,3 
Charlotte Mary Hespe,4 Menai Johnson,5 Rodney Stosic,6 David B Price   7,8
To cite: Bosnic- Anticevich S, 
Smith P, Abramson M, et al.  
Impact of allergic rhinitis on the 
day- to- day lives of children: 
insights from an Australian 
cross- sectional study. BMJ Open 
2020;10:e038870. doi:10.1136/
bmjopen-2020-038870
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 038870).
Received 27 March 2020
Revised 31 August 2020
Accepted 25 September 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Sinthia Bosnic- Anticevich;  
 Sinthia. Bosnic- Anticevich@ 
sydney. edu. au
Original research
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Study design and objective Cross- sectional, 
observational survey to describe the impact of allergic 
rhinitis (AR) on Australian children (2 to 15 years).
Methods Participants (n=1541), parents of children 
aged 2 to 15 years, provided information on behalf of 
themselves and one eligible child in their household 
using a custom- built online questionnaire. Children were 
allocated to case (AR) or control (No AR) analysis groups 
based on a validated screening questionnaire.
Statistical methods The study sample was stratified on 
age: primary analysis population (6 to 15 years, n=1111; 
AR=797, No AR=314); exploratory population (2 to 5 
years). The primary endpoint, parent- perceived burden, 
was quantified using a validated measure of health status 
and analysed via comparison of means.
Results The majority of AR cases were treated (730/797; 
90.3%) and classified as having moderate- severe, 
intermittent AR (549/797; 68.9%). Half reported adequate 
symptom control in the prior 2 weeks (389/797; 48.8%; 
OR=4.04; 95% CI (CI) 2.24 to 7.31). Having AR was 
associated with worse overall health status (7.4 vs 
8.4, mean difference (least squares mean difference 
(LSMD))=−0.99; 95% CI −1.18 to −0.79), fewer days 
being happy (22.2 vs 25.9, LSMD=−3.68; 95% CI −4.82 
to −2.54) and more days of poor physical (2.82 vs 0.78, 
LSMD=2.04; 95% CI 1.61 to 2.47) and emotional (2.14 
vs 0.67, LSMD=1.47; 95% CI 1.02 to −1.92) health 
compared with not having AR. All of these outcomes were 
significantly (p<0.05) worse in children who reported 
inadequate symptom control. Having AR negatively 
impacted on schoolwork, sleep and other activities, and 
increased the likelihood of having comorbidities.
Conclusion The parent- perceived burden of AR in 
Australian children is high and it impacts many areas 
of day- to- day living. Inadequate symptom control is a 
key driver of the extent of this impact. Opportunities to 
optimise the management of AR in children include the 
adoption of self- assessment tools to gauge and monitor 
adequacy of symptom control.
INTRODUCTION
Allergic rhinitis (AR), an IgE- mediated, 
chronic inflammatory disorder affecting the 
nasal mucosa, is characterised by episodes 
of repeated sneezing, rhinorrhoea and nasal 
congestion, often accompanied by itching of 
the eyes, nose and palate.1 Pharmacological 
treatment aims to achieve symptom control, 
but current Allergic Rhinitis and its Impact on 
Asthma (ARIA) guidelines suggest the need to 
take account of multiple factors beyond effi-
cacy, speed of onset and safety when selecting 
pharmacotherapy for patients to encompass 
patient preferences, symptom severity, prior 
treatments, self- management strategies and 
the effects of AR on sleep and work produc-
tivity.2 This reflects an increasing recognition 
that the interlinked concepts of disease severity 
and control are complex in AR. Rather than 
equating severity directly with physiological 
function, patients with AR tend to equate 
severity with the negative impact that the aller-
gies have on their lives.3 Understanding what 
drives this negative impact of AR is important; 
and is further heightened where treatments for 
this condition are available in the pharmacy 
setting where patients often self- select.
Strengths and limitations of this study
 ► This study used objective measures to quantify the 
negative impact of paediatric allergic rhinitis on 
health status, emotional well- being, physical health, 
school and sleep.
 ► All data were parent- reported and were collected 
using a customised online survey questionnaire, 
which included relevant validated tools.
 ► The International Study of Asthma and Allergies 
in Childhood questionnaire provided the basis for 
screening participants and was used to allocate 
children to case or control groups for analysis.
 ► The data revealed some interesting findings, notably 
the significant role of adequacy of symptom control, 
and raised questions about the level of parental 
knowledge regarding the medication their child is 
taking.
 ► The validity of the data was limited due to meth-
odological constrains, including online sampling, 
inability to verify sample representativeness and 
collection of parent- reported data rather than those 
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Health- related quality of life (HR- QoL) is a complex 
and multidimensional concept used as a marker of disease 
impact beyond clinical impact, morbidity or mortality. It is 
often used to capture subjective perceptions and objective 
assessment of a patient’s health and well- being.4 HR- QoL 
in children with AR is an important and emerging area of 
interest, primarily due to the fact that the impact of AR 
on the day- to- day lives of individuals can be felt beyond 
the severity of symptoms experienced. In their review of 
27 studies of children with AR, aged 10 to 19 years, Blaiss 
et al5 highlighted the negative impact of AR on several 
aspects of day- to- day living including: daily functioning, 
sleep, absenteeism, school productivity and academic 
performance. Adolescents with AR have high rates of 
somatisation, anxiety and depression, less resistance to 
stressful situations, and exhibit more hostility, impulsivity 
and rapid changes in interest. Parental assessment of 
the impact of AR on the day- to- day lives of children with 
AR indicates that AR makes their child unhappy, upset, 
angry and embarrassed.6 In practical terms, HR- QoL can 
be used to describe the way in which health status affects 
quality of life.7 Some of the most important research 
exploring the impact of AR on the day- to- day lives of chil-
dren in the USA have used the concept of ‘health status’ 
as a means of determining the burden of AR.8 It is in 
recognition of this research, and the high prevalence of 
AR, that we focus on AR in children.
Previous Australian data reported a prevalence of AR 
of approximately 12.9% in children aged 6 to 7 years 
and 19.3% in children aged 13 to 14 years.9 More recent 
data suggest a higher, and rising,10 prevalence: 15.1% to 
37.8% in adolescents aged 12 to 15 years in Europe11 and 
24.8% among children aged 14 to 17 years in the USA.12 
Data from an Australian longitudinal birth cohort study 
(Perth Infant Asthma Follow- up (PIAF) study) demon-
strated a rapid increase in the development of AR over 
childhood (7% at age 6 years, 18% at age 11 years and 
increasing to 24% by age 18 years).13 However, despite 
this high prevalence, published Australian data on the 
impact and management of AR in children are minimal 
and outdated.14
To address this gap, we conducted a national, online 
survey to generate contemporary data describing the 
burden of AR on the day- to- day lives of Australian chil-
dren (2 to 15 years), with the aim of identifying gaps and 
opportunities for optimising care in the future. Inherent 
difficulties in properly identifying AR in young children 
(2 to 5 years) were addressed by the study sample being 
stratified on age with the primary analysis population 
encompassing children 6 to 15 years and an exploratory 
population encompassing the younger children (2 to 5 
years). We report here the primary study results.
METHODS
The survey was conducted between 15 October 2018 and 
12 November 2018. The study sample was derived from 
three ISO- accredited research- only panels of respondents 
for online consumer research in Australia (Ipsos i- Say 
180 000 members, Research Now/Survey Sampling 
International 400 000 members and Pure Profile 250 
000 members). Panel members completed a series of 
screening questions, including inclusion and exclusion 
criteria, and eligible respondents provided informed 
consent prior to accessing the survey. Eligible partic-
ipants were aged 21 years or over, currently residing in 
Australia and the parent/guardian of at least one child 
aged 2 to 15 years. Participants provided information on 
behalf of themselves and one eligible child in their house-
hold. Participants with multiple eligible children were 
randomly allocated a specific child on which to answer 
questions.
Data collection and cohort description
All data were parent- reported, and collected using a 
customised online survey questionnaire, which was self- 
administered once. The questionnaire (online supple-
mental file 1) comprised a series of closed- answer 
questions, incorporating relevant validated tools and 
other questions developed empirically through review of 
the AR literature and other health surveys.
The questionnaire explored 11 domains: (1) screening 
(International Study of Asthma and Allergies in Child-
hood (ISAAC) questionnaire),15 (2) family medical 
history, (3) parent- perceived burden (as assessed by the 
validated single health status question;16 and the vali-
dated Healthy Days questionnaire17 and impact of AR 
on day- to- day living (adapted from Pediatric Allergies in 
America Survey)),18 (4) beliefs about medicines (Beliefs 
about Medicines questionnaire),19 (5) knowledge and 
beliefs about allergies (knowledge, attitude and practice 
questions in AR and asthma),20–22 (6) AR classification 
(ARIA criteria),1 23 (7) AR diagnosis, (8) AR triggers and 
testing, (9) AR symptoms (Contre les MAladies Chro-
niques pour un VIeillissement Actif (MACVIA)- ARIA vali-
dated visual analogue scales (VAS)3 24 25), (10) symptom 
control (Control of Allergic Rhinitis and Asthma Test for 
Children)26 and (11) AR management strategies. The 
length of the questionnaire was a key consideration; to 
minimise bias resulting from questionnaire fatigue, data 
collected about the survey respondents (parents/guard-
ians) were minimal, with the majority of data relating to 
the specified child on whose behalf the questionnaire was 
being completed.
The ISAAC questionnaire15 provided the basis for 
screening participants and was used to allocate respon-
dents’ children to case or control groups for analysis. 
Cases (AR) were defined as children with symptoms of 
AR that were not associated with a cold/influenza, and 
controls (No AR) were defined as children without 
symptoms of AR. Within the AR group, a subgroup was 
defined based on information provided that the child 
was currently using an allergy medication, where ‘treated 
AR’ had selected one or more types of medicines from a 
list, while those allocated to ‘untreated AR’ had selected 
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Burden of AR was determined based on four questions: 
a single validated question, ‘In general, how would you 
describe your child’s health?’ to provide a measure of 
health status, and three questions to assess the number 
of healthy days per month, as reflected in the number of 
the number of days in the last month the child could be 
described as being (a) healthy (happy and full of energy), 
(b) had poor physical health or (c) had poor emotional 
health. These four questions were derived from the vali-
dated Centers for Disease Control and Prevention (CDC) 
Healthy Days Core Module17 and the Pediatric Allergies 
in America Survey.18 The original, validated, health status 
question was answered using a 5- point Likert scale (excel-
lent, very good, good, fair or poor).17 To provide a quan-
titative value for statistical analyses, it was administered 
using a 10 cm VAS (0= poor; 10= excellent). To determine 
the impact of AR on day- to- day living, questions used in 
the Pediatric Allergies in America Survey18 were modified 
in order to capture data relating to performance at school 
and in other activities, sleep duration, sleep quality, absen-
teeism and presenteeism. Taking into consideration the 
lower target age of the children in the survey was 2 years, 
for pragmatic reasons the questionnaire was answered 
by an adult on behalf of the child, hence all findings are 
reported as being parent- perceived.
Patient and public involvement
The research question and outcomes measures were 
informed by the results of prior published research in 
paediatric AR patients. However, at the time of protocol 
development, a review had identified a number of 
important data gaps, noting few recent data on the 
impact of AR in adolescents and questioned the rele-
vance of available evaluations of HR- QoL in the current 
social landscape.5 Patients were not involved in the design 
of the survey questionnaire, the conduct of the study or 
reporting of the results.
Sample size
The primary endpoint was parent- perceived burden 
(health status) in children aged 6 to 15 years in case (AR) 
versus control groups (no AR). It was determined that the 
study would require a sample of at least 1000 children 
for univariate logistic regression and 1100 children for 
multivariable logistic regression, assuming the sample was 
children aged 6 to 15 years, with an expected symptom 
prevalence of 4% (4.45%,27 an OR of 1.5 (1.5 among chil-
dren aged 6 to 17 years5), an alpha of 5% (95% CI), a 
power of 80% and a 30% multiple correlation with other 
covariates. To allow for the exploratory analysis in young 
children, the sample was extended proportionately to 
the age range 2 to 5 to maintain the same power. Sample 
selection quotas were stratified based on the child’s age, 
gender, geographical location and meeting case/control 
criteria. Children meeting case criteria were also stratified 
based on AR classification, management and manage-
ment type.
Statistical analysis
Variables included prevalence, family history, parent- 
perceived burden16 17 and impact,18 symptoms, diagnosis, 
triggers and management. Baseline demographic vari-
ables (child’s age and gender) were used as criteria to test 
for differences. All information was summarised using 
descriptive statistics for continuous data and frequency 
tables for categorical data. Summaries were provided 
based on relevant analysis samples: controls (No AR), all 
cases (AR), AR cases treated and AR cases not treated. 
Observations with missing values were excluded and 
answers of ‘Don’t Know’ were replaced with missing 
values.
Data were analysed using the χ2 test for two- way tables 
and by binary logistic or multinomial models for variables 
with more than two levels. All statistical analyses were 
performed at the 5% significance level using two- sided 
tests or two- sided CIs. For two- way tables, OR with 95% 
CI and p values were created to quantify any associations. 
Additional analyses were conducted to understand the 
relationships, multi- level associations and interactions 
and control for potentially confounding factors. The 
analysis was built progressively through phases, by first 
understanding the univariate relationships (for contin-
uous variables) or associations (for categorical variables), 
and then incorporating analysis and modelling which 
brought in more than one variable to account for inter-
actions or potentially confounding factors. The variables 
incorporated in the secondary modelling included vari-
ables identified in the initial analysis with a cut- off of 
p<0.05.
The level of parent- perceived burden was determined 
via comparison of means, 95% CI for the means and 
their differences and t or z tests for the following groups: 
cases (AR) versus controls (No AR), cases (AR) treated 
versus not treated, and cases (AR) with good versus 
poor symptom control. Where there were more than 
two groups, analysis of variance was applied to test for 
a significant difference between groups. Depending on 
the group, analyses conducted were: distribution and 
comparison of means (least squares means (LSM)), 
generalised linear models (GLM), contingency tables and 
OR, and GLM model with interactions. This analysis was 
applied to each of the four questions used to determine 
burden: health status, the number of healthy days in the 
last 30 days and the number of unhealthy days in the last 
30 days (a combined mean of physically unhealthy days 
and emotionally unhealthy days).17 Covariates identified 
based on the outcome of the baseline variables analyses 
were then included as independent variables along with 
group allocation (AR or No AR) and treatment type in 
multiple linear regression of the above mean parent- 
perceived burden measures. Summaries and statistical 
analyses were generated using Q- research software 
(V.5.3.2, Displayr, Chicago, Illinois) and SAS (V.9.4, SAS 
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RESULTS
Of the 2980 potential participants screened, 1541 met 
the inclusion criteria and completed the survey. Approx-
imately two- thirds of respondent were female and their 
mean age was 42 years (online supplemental table 1). 
The primary analysis sample comprised 1111 children, 
aged 6 to 15 years (figure 1); the majority of AR cases 
were being treated (730/797; 90.3%) and were classified 
as having moderate- severe, intermittent AR based on the 
ARIA criteria (549/797; 68.9%).
Demographics
There was no statistically significant difference between 
the mean ages of AR case and control children. Children 
treated for AR, were older than those not treated (11.5 
vs 10.1 years, 95% CI −2.12 to −0.53). Parental AR was 
associated with significantly increased odds of AR in their 
offspring (OR 5.21, 95% CI 3.78 to 7.18) and there were 
statistically significant relationships between having AR 
and sinusitis, asthma, cough, recurrent wheezing, hives, 
nasal polyps or food allergy. Children with AR were 
significantly more likely to have undergone ear, nose and 
throat procedures than those without AR (table 1). In the 
past 12 months, doctor visits were reported significantly 
more frequently in children with AR than those without 
(3.2 vs 1.4 visits, p<0.001). After hay fever, the three most 
common reasons for seeking a doctor’s advice in children 
Figure 1 STROBE flowchart of participants, group allocation: AR/No AR based on the International Study of Asthma and 
Allergies in Childhood questionnaire;15 mild/moderate- severe and intermittent/persistent based on the Allergic Rhinitis and its 
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with AR were cough, respiratory tract infections and 
asthma, all of which were significantly higher than in chil-
dren without AR (table 1).
AR symptoms and adequacy of control
The average age at symptom onset was 6.7 years (treated 
AR) and 6.2 years (untreated AR). Parents of children 
with AR reported that runny nose, nasal congestion, itchy 
eyes and repeated sneezing were the four most bother-
some symptoms (online supplemental table 2). When 
the level of bother from each symptom was reported 
using a 10 cm VAS, facial pain, difficulty getting to sleep, 
disturbed sleep, distractibility and irritability were the 
most frequently reported moderate- severely bothersome 
symptoms (figure 2).
Overall, half of the children with AR were reported 
to have adequate symptom control (VAS score of ≤5 on 
a 10 cm scale) over the past 2 weeks (389/797; 48.8%). 
The majority of children currently treating their AR were 
using tablets/liquids (453/730, 62%), half were using 
nasal sprays (365/730, 50%) and one in three were using 
eye drops (211/730, 29%). The majority of children who 
were treating their AR had been advised to do so by a 
healthcare professional (general practitioner: 372/730 
(51%), pharmacist: 175/730 (24%) and specialist: 80/730 
(11%)). However 10% (73/730) of children were being 
managed based on the decisions of their parents.
Irrespective of the medication class, the majority of 
children began using their medication either at the 
onset of symptoms or the onset of the allergy season 
(online supplemental table 3). Over one- third of chil-
dren (263/730, 36%) who had been identified as treating 
their AR had taken medication on the day of the survey. 
The mean bother score was higher in these children 
(6.14±2.04) than in those who had not taken their medi-
cation that day (3.20±2.68).
Burden and impact of AR
Based on the single validated question, ‘In general how 
would you describe your child’s health?’ to determine 
health status, children with AR had significantly higher 
parent- perceived burden than did those without AR 
(figure 3). Subgroup analyses showed that these differ-
ences remained statistically significant for comparisons of 
Table 1 Medical history and doctor visits. Data presented as N (%)








Tonsils removed 127 (15.9%)* 19 (6.1%) 118 (16.2%) 9 (13.4%)
Adenoids removed 104 (13.0%)* 19 (6.1%) 98 (13.4%)* 6 (9.0%)
Tubes put in his/her ears 69 (8.7%)* 12 (3.8%) 67 (9.2%)* 2 (3.0%)
Nasal or sinus surgery 63 (7.9%)* 3 (1.0%) 59 (8.1%) 4 (6.0%)
Required braces for their teeth 195 (24.5%)* 50 (15.9%) 182 (24.9%)* 13 (19.4%)
None of the above 446 (56.0%) 240 (76.4%)* 400 (54.8%) 46 (68.7%)*
Reasons for visits to the doctor Cases (AR) n=729† Controls (No AR) 
n=190†
Cases (AR) treated 
n=672†
Cases (AR) not 
treated n=57†
Asthma 38 (18.9%)* 18 (9.5%) 127 (18.9%) 11 (19.3%)
Sinusitis 84 (11.5%)* 3 (1.6%) 81 (12.1%) 3 (5.3%)
Hay fever/AR (nasal and/or eye allergy 
symptoms)
324 (44.4%)* 1 (0.5%) 311 (46.3%)* 13 (22.8%)
Sleep disturbances 45 (6.2%)* 2 (1.1%) 42 (6.3%) 3 (5.3%)
Adenoids/tonsils hypertrophy 50 (6.9%)* 2 (1.1%) 48 (7.1%) 2 (3.5%)
Eczema (atopic dermatitis) 72 (9.9%)* 6 (3.2%) 67 (10.0%) 5 (8.8%)
Vaccinations 121 (16.6%)* 17 (8.9%) 116 (17.3%)* 5 (8.8%)
Cough 322 (44.2%)* 62 (32.6%) 295 (43.9%) 27 (47.4%)
Nasal polyps 26 (3.6%)* 1 (0.5%) 26 (3.9%)* 0 (0.0%)
Hives (urticaria) 21 (2.9%)* 1 (0.5%) 20 (3.0%) 1 (1.8%)
Respiratory tract infection 139 (19.1%)* 18 (9.5%) 134 (19.9%)* 5 (8.8%)
Urinary tract infection 24 (3.3%) 4 (2.1%) 20 (3.0%) 4 (7.0%)
Acne 39 (5.3%) 5 (2.6%) 37 (5.5%) 2 (3.5%)
Other 183 (25.1%) 114 (60.0%)* 161 (24.0%) 22 (38.6%)*
*Statistically significant difference between groups (cases versus controls; cases treated versus not treated) at 95% CI. The list of reasons 
was prespecified in the survey questionnaire.
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children with inadequate symptom control versus good 
symptom control and of children with moderate- severe 
versus mild AR, but not for treated versus untreated 
cases (figure 3). Having AR, poor symptom control and 
moderate- to- severe disease were also associated with fewer 
healthy days and more unhealthy days (poor emotional 
and physical health) per month (figure 4). There was a 
significant association between AR classification, treat-
ment and adequacy of symptom control (figure 5). Based 
on health status, parent- perceived burden was least in 
untreated children who had mild AR and good symptom 
control (LSM health score: 8.24; 95% CI 7.68 to 8.80) and 
greatest in untreated children who had moderate- severe 
AR and inadequate symptom control (LSM health score: 
6.58; 95% CI 5.72 to 7.44).
The burden of AR was greatest in children with co- mor-
bidities (figure 6A). Parent- perceived burden was lowest 
in children with AR who also had other conditions (LSM 
7.27; 95% CI 7.07 to 7.47), but was not significantly lower 
than in children with AR and no other conditions (LSM 
7.47; 95% CI 7.32 to 7.62). Parent- perceived burden 
was significantly lower in children with AR, either with 
or without comorbidities, than in those without AR with 
(LSM 8.03; 95% CI 7.78 to 8.53) or without (LSM 8.58; 
95% CI 8.38 to 8.78) comorbidities. This trend was also 
seen in the number of healthy days (figure 6B), days of 
poor physical health and days of poor emotional health 
per month (figure 6C).
Having AR versus not having it was associated with 
significantly reduced ability to perform schoolwork and 
other activities. Children accomplished less than they 
would usually have done at school or in other activities, 
and a reduced level of care was taken when performing 
Figure 2 Proportion of children with AR in whom symptoms 
were moderate- severely bothersome*. *Defined as a score 
between 6 and 10 on a 10 cm visual analogue scale (0 cm= 
not at all bothersome and 10 cm= extremely bothersome (as 
bad as they can get)).34 AR, allergic rhinitis.
Figure 3 Parent- perceived burden: health status in children 
aged 6 to 15 years.*Health status was based on the single 
question, ‘In general, how would you describe your child’s 
health?’,16 18 adapted to be answered on a 10 cm VAS (0= 
poor health and 10= good health). Mean score was derived 
from the cut- off criteria: VAS<2= very poor; 2≤VAS<4= poor, 
4≤VAS<6= good, 6≤VAS<8= very good and 8≤VAS≤10= 
excellent). AR, allergic rhinitis; ns, not significant; VAS, visual 
analogue scale.
Figure 4 Parent- perceived burden: healthy and unhealthy 
days per month in children aged 6 to 15 years. The number 
of days in the last month the child was either healthy (happy 
and full of energy), had poor physical health or had poor 
emotional health were measured based on questions derived 
from the Centers for Disease Control and Prevention’s 
Healthy Days Core Module17 and the Pediatric Allergies 
in America Survey.18 *Unhealthy days= number of days of 
poor emotional health and number of days of poor physical 
health combined. †Statistically significant difference between 
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schoolwork and other activities (table 2). Between- group 
comparisons showed that, among all children with AR, 
these activities were affected in significantly more chil-
dren who had poor symptom control (versus good 
symptom control), in those with moderate- to- severe 
symptoms (versus mild symptoms) and those who were 
currently treating their AR (versus not currently treating) 
(table 2). Having AR was also associated with a reduced 
duration of sleep (8 hours or less per night: AR 494/797 
(62%) vs No AR 126/314 (40%), p<0.05), poorer sleep 
quality and higher rates of absenteeism (table 2).
Parents’ knowledge and beliefs about AR
As part of the survey, parents were asked if their child 
ever had hay fever. These data were then compared with 
children classified as having AR (AR cases) based on the 
answers that the parents gave to the ISAAC questions15 
later in the survey. AR was not always recognised by the 
parents: overall, a history of AR was not reported in 
118/797 (15%) of the children who were classified as 
having AR based on the ISAAC questions. Most parents 
(669/797; 84%) believed that AR could significantly 
impair well- being, but their understanding of causes was 
poor; 375/797 (47%) believed it could only be caused 
by a reaction to something in the air outdoors, 128/797 
(16%) believed that it was caused by a virus and 112/7979 
(14%) believed that it was contagious. Parents who 
had sought advice from a healthcare professional had 
primarily received written or verbal information about 
available treatment options (274/797; 34%), adminis-
tration approaches (dosing regimen (169/797, 21%), 
how to use (191/797, 24%) and side effects (191/797, 
24%)). Few received information about the condition 
itself (117/797, 15%), and two- third (509/797, 64%) of 
parents indicated that they would benefit from having 
more information about AR.
DISCUSSION
This study has confirmed that having AR significantly 
impacts a child’s life as reported by parents. Among 
Australian children, aged 6 to 15 years, having AR was 
associated with greater parent- perceived burden, lower 
health status, fewer days of being healthy and more days 
of being unhealthy (poor physical or emotional health). It 
significantly reduced the child’s ability to perform school-
work and other activities, was associated with children 
accomplishing less than they would usually have done at 
school or in other activities, and reduced the level of care 
taken when performing schoolwork and other activities. 
Absenteeism and the likelihood of having comorbidities 
were increased, while sleep duration and quality were 
reduced.
Parent- perceived burden was highest in children who 
were not treated, who also had moderate- severe AR and 
reported inadequate symptom control. Statistical model-
ling, undertaken to help better define what was contrib-
uting to this parent- reported burden, found the most 
important overall factor leading to a lower health status was 
inadequate symptom control. Despite the majority of chil-
dren being treated, half had inadequate symptom control 
(VAS score of >5 on a 10 cm scale). Parents reported that 
a large proportion of children used their medication only 
after their symptoms had started or when symptoms were 
very bothersome. While this may reflect that the majority 
of treated children were classified as having intermittent 
AR (mild: 19.7%, moderate- severe: 71.2%), and reflects 
on- demand treatment approaches observed in adults with 
AR,28 it does not account for optimal pharmacology. For 
example, oral antihistamines have a rapid onset of action 
(1 to 2 hours), while for intranasal corticosteroids (INCS) 
the onset of action is 7 to 12 hours and it can take up to 2 
weeks for maximum benefit to be achieved.29 Established 
guidelines support that use of INCS on an as- needed basis 
is less effective than continuous use.30
In an attempt to determine the relationship between 
treatment and impact of AR, participants were asked to 
report on whether their child had used their allergy medi-
cation that day, while also reporting on how bothersome 
Figure 5 Parent- perceived burden: interaction between AR 
classification, receipt of treatment and adequacy of symptom 
control in children with AR aged 6 to 15 years. *Health status 
was based on the single question, ‘In general, how would you 
describe your child’s health?’,16 18 adapted to be answered 
on a 10 cm VAS (0= poor health and 10= good health). 
Mean score was derived from the cut- off criteria: VAS<2= 
very poor; 2≤VAS<4= poor, 4≤VAS<6= good, 6≤VAS<8= 
very good, 8≤VAS≤10= excellent. Statistically significant 
differences in health status between seven comparisons: 
treated and mild AR and good control versus treated and 
moderate- severe AR and good control (p=0.0008), treated 
and mild AR and good control versus treated and moderate- 
severe AR and poor control (p<0.0001), treated and mild AR 
and good control versus not- treated and moderate- severe 
AR and poor control (p=0.0081), treated and mild AR and 
poor control versus treated and moderate- severe AR and 
poor control (p=0.0126), not- treated and mild AR and good 
control versus treated and moderate- severe AR and poor 
control (p=0.001), not- treated and mild AR and good control 
versus not- treated and moderate- severe AR and poor control 
(p=0.0181), treated and moderate- severe AR and good 
control versus treated and moderate- severe AR and poor 
















pen: first published as 10.1136/bm






8 Bosnic- Anticevich S, et al. BMJ Open 2020;10:e038870. doi:10.1136/bmjopen-2020-038870
Open access 
the AR symptoms were that day. The results were counter- 
intuitive to what would have been expected. AR symptoms 
were reported as being more bothersome in those chil-
dren who had taken their medication that day compared 
with those who had not. While these data could be inter-
preted to mean that the medication taken had not worked, 
it is more likely (based on the order of the questions) that 
the children had been given medication because their 
symptoms had been bothersome that day. This is consis-
tent with an approach of treating to alleviate the impact 
of AR, rather than based on disease severity. Community 
pharmacy research, conducted among Australian adults 
with AR has demonstrated that the majority (70%) self- 
select over- the- counter medications, but only 15% select 
an appropriate medication for their condition based on 
symptom severity.31 32 Symptom severity was found not to 
be a driving factor in medication choice, with patients 
reporting that they only sought advice from the pharma-
cist when they perceived their symptoms to be sufficiently 
bothersome to impact on their day- to- day lives.33
This study has a number of limitations. The survey ques-
tionnaire was custom- designed for this research activity 
and was not validated in its entirety prior to use. However, 
it drew on a combination of validated tools and questions 
previously used in similar surveys in paediatric AR. The term 
‘burden’ was used to discuss the effect of AR on health and 
‘impact’ to discuss its effect on activities of day- to- day living, 
such as schooling and sleep. The measures of burden are 
determined based largely on the CDC Healthy Days ques-
tionnaire17 and the measures of impact on questions in the 
Pediatric Allergies in America Study.18 Validity of the use of 
the single question to measure health status is supported in 
the literature16 and has previously been adapted and used 
in the AR setting to enable an adult to answer on behalf of 
a child in their care18 Where possible, the survey question-
naire used VAS scales; thereby conforming to established, 
quantitative methods in other areas of AR research as a 
valid measure.34–36 The representativeness of the sample 
to that of the Australian population has been difficult 
to verify given the limited amount of participant demo-
graphic data collected. Based on the available data, the 
sample was slightly older, had a higher level of education 
and a higher household income than average Australians. 
This may have occurred due to the online nature of the 
survey methodology and may have introduced some bias, 
given that we found a higher household income was asso-
ciated with an increased propensity to treat AR. The study 
was set up to collect parental perceptions rather than the 
Figure 6 Parent- perceived burden: interaction between AR and comorbidities in children aged 6 to 15 years.*Health status 
was based on the single question, ‘In general, how would you describe your child’s health?’,16 18 adapted to be answered 
on a 10 cm VAS (0= poor health and 10= good health). Mean score was derived from the cut- off criteria: VAS<2= very poor, 
2≤VAS<4= poor, 4≤VAS<6= good, 6≤VAS<8= very good, and 8≤VAS≤10= excellent. †The number of days in the last month the 
child was healthy (happy and full of energy), had poor physical health and had poor emotional health were measured based 
on questions derived from the Centers for Disease Control and Prevention’s Healthy Days Core Module17 and the Pediatric 
Allergies in America Survey18. ‡Unhealthy days=number of days of poor emotional health and number of days of poor physical 
health combined. (A) overall health status* (B) number of healthy days in the last month† (C) number of unhealthy days‡ in the 
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views of children, this may have posed some limitations on 
the validity reliability of the data, due to proxy reporting 
bias, particularly in adolescents who were not given the 
opportunity to answer for themselves.
The PIAF study demonstrated the impact of parental 
asthma, eczema and AR on the odds of their offspring 
developing these conditions.13 Similarly, in our study, 
children with AR were significantly more likely to report a 
range of medical conditions (eg, asthma, cough, eczema, 
sinusitis and food allergy) in the family (parents/siblings 
and proband children) relative to children without AR. 
However, the survey questionnaire listed conditions for 
the respondents to select from, potentially introducing 
reporting bias, and there were no clinical examinations 
or objective tests to verify a diagnosis of AR, both of which 
limit the interpretation of the data.
In moving forward with the findings of this research, 
it is important to consider the implications in context 
with available AR management guidelines. ARIA guide-
lines developed over the past 20 years have incorpo-
rated evidence- based, integrated care approaches to AR 
management. Increased understanding of the impor-
tance of impact and adequacy of control to sufferers has 
lead to a paradigm shift.37 In recent years, the MACVIA- 
ARIA Sentinel NetworK has developed and validated VAS 
scales to evaluate the extent of AR symptom control.3 25 
Well- controlled AR has previously been defined as a VAS 
of score of 2 or less.38 The new ARIA guidelines for adults 
and adolescents recommend a step- up/step- down algo-
rithm based on patient- report of symptom control assessed 
via a VAS, with a step- down if the score is <2, continuing as 
is for scores of ≥2 to<5, and stepping up if the score is ≥5.2 
The rationale being that better reflecting patients’ needs 
and preferences will improve overall patient satisfaction 
and adherence, thereby optimising management. Given 
the availability of over- the- counter allergy medicines, and 
high levels of self- diagnosis and self- management of AR, 
the principles behind these guidelines and the use of VAS 
scales for self- assessment have been incorporated into 
care pathways, algorithms and shared decision support 
systems for use in the community pharmacy setting.37 39 A 
recent review of AR adds to this, supporting the view that 
shared decision- making can help to better equip patients 
to make appropriate decisions for optimal disease 
control.40
Prior research has demonstrated that children with AR 
as young as 8 years of age are able to use self- assessment 
questionnaires, including VAS scales to report measures 
of disease severity and impact.41 The availability of app- 
based self- assessment tools, such as the MASK- Air Allergy 
Diary, opens up the concept that some children may be 
able to take a more active role in documenting the impact 
of the AR, providing opportunities to enhance shared 
decision making.
CONCLUSION
The parent- perceived burden of AR in Australian chil-
dren aged 6 to 15 years is high and impacts many areas of 
day- to- day living, including emotional well- being, physical 
health, school and sleep. Inadequate symptom control is a 
key driver of the extent of that impact. Parents have many 
misconceptions about AR and its management. Oppor-
tunities to optimise the management of AR in children 
include parental education, regular review and adoption 
of self- assessment tools to gauge and monitor adequacy of 
symptom control.
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SURVEY QUESTIONS 
All questions will be asked of parents/guardians, who will answer on behalf of their child aged 
2-15 years.  
NOTES:  
Throughout this document the term term “child/children” refers to a child or ward of the adult 
who is answering the survey questions. 
Text in red is instructional text and will ntot be seen by the participant. 
 
A. INCLUSION CRITERIA 
1 What is your gender?  Male 
Female 
2 In what year were you born (enter your response as a 4-
digit number; e.g. 2018)? 
 If <21 years: 
Exit survey 
3 How many children between the age of 2 and 15 years, 
for whom you are the parent or guardian, live in your 
household? 
 If none: 
Exit survey 
 
 SEEK INFORMED CONSENT TO CONTINUE WITH SURVEY 
 
B. PARTICIPANT DEMOGRAPHY 
1 What is your highest completed educational 
qualification? 
 
Less than Year 12 or equivalent 
Year 12 or equivalent (HSC/Leaving 
certificate) 
Vocational Qualification 
Bachelor degree  
Masters degree 
Doctorate 
Rather not say  
2 Which of the following best describes the area you live 
in? 
 
Urban/capital city  
Regional  
Rural 
3 Please indicate your current annual (yearly) pre-tax 
household income  
 





Rather not say  
 
 
4 We would like to find out the age and gender for each 
child between the age of 2 and 15 years in your 
household for whom you are the parent or guardian.  
















C. SCREENING [Case/Control group allocation] [Based on ISAAC questions
[1]
] 
 Now thinking specifically about your [AGE AND  Applies only 
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GENDER OF CHILD; e.g. son aged 12 years] if >1 eligible 
child 
1 Has your child ever had a problem with sneezing, or a 
runny, or blocked nose when he/she DID NOT have a 
cold or the flu? 
Yes 
No 
If no, skip to 
Q 6 
2 In the past 12 months, has your child ever had a 
problem with sneezing, or a runny, or blocked nose 
when he/she DID NOT have a cold or the flu? 
Yes 
No 
If no, skip to 
Q 6 
3 In the past 12 months, has this nose problem been 




4 In which of the past 12 months, did this nose problem 














5 In the past 12 months, how much did this nose problem 
interfere with your child’s daily activities? 
Not at all 
A little 
A moderate amount 
A lot 
 




D. FAMILY MEDICAL HISTORY & IMPACT [Some questions developed based on information 
in Zicari, 2013 
[2]
] 
1 Have you ever been told by a doctor (diagnosed) that 
you have any of the following conditions? (Please 
select all that apply) 
Asthma 
Sinusitis  
Hayfever/allergic rhinitis (nasal and/or 
eye allergy symptoms) 
Sleep disturbances  
Adenoids/tonsils hypertrophy  







Oral allergy syndrome  
Recurrent respiratory infections  
Dental malocclusion 
None of the above 
2 Excluding the child that you are answering this survey 
about, have you been told by a doctor (diagnosed) that 
any of your other children aged 2-15 years have any of 




rhinitis (nasal and/or 
eye allergy symptoms) 




if >1 eligible 
child 
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None of the above 
 Now thinking specifically about your [AGE AND 
GENDER OF CHILD; e.g. son aged 12 years] 
 Applies only 
if >1 eligible 
child 
3 Has this child ever been told by a doctor (diagnosed) 





rhinitis (nasal and/or 
eye allergy symptoms) 















None of the above 
 
4 Has this child ever had or likely to have any of the 




Tubes put in his/her 
ears 
Nasal or sinus surgery 
Required braces for 
their teeth 
None of the above 
 
5 During the past 12 months, how many times have you 













6 What was the reason for this visit to the doctor? (Please 
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Hayfever/allergic 
rhinitis (nasal and/or 
eye allergy symptoms) 















one in Q 
prior] 
7 During the past 12 months, how many days have you 
had to take off from work to care for your child because 






















1 Using the scale below, in general how would you 
describe your child’s health? 
 
VAS SCALE: 0-10 cm  
(0 = very poor, as bad as it can get, 10 = excellent, 
as good as it can get) 
 
 Single question 
supported by 
literature.[6] 
2 During the past 30 days, for about how many days 
has your child appeared happy and full of energy? 
 
Number of days 
None 
Don’t know/not sure 
Adding up the total 
in a 30-day period 
can be used to 
determine the 
number of normal 
days versus days 




3 During the past 30 days, for about how many days 
has poor physical health kept your child from 
doing their usual everyday activities?  
Number of days 
None 
Don’t know/not sure 
4 During the past 30 days, for about how many days 
has poor emotional health kept your child from 
doing their usual everyday activities?  
Number of days 
None 
Don’t know/not sure 
5 During the past 4 weeks, has your child had 
difficulty in performing schoolwork or other 
activities because of his or her health? 
 
Yes – schoolwork only 
Yes – other activities only 
Yes – schoolwork and other activities  
No 
6 During the past 4 weeks, has your child 
accomplished less than he or she would usually 
have done at school or in other activities because 
of his or her health? 
Yes – school only 
Yes – other activities only 
Yes – school and other activities  
No 
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7 During the past 4 weeks, has your child done 
schoolwork or other activities less carefully than 
they usually would because of his or her health? 
Yes – school only 
Yes – other activities only 
Yes – school and other activities  
No 
8 During the past 4 weeks, how many hours of sleep 
a night has your child usually had? 
 




10 or more 
 
9 During the past 4 weeks, has your child had any of 










Waking up tired 
Daytime sleepiness 
None of the above 
 
10 During the past 12 months, how often has your 
child needed to take time off school because he/she 
was unwell? 
Once a week 
Once a month 
Once a term 
Once a semester 
Once a year 




F. BELIEFS ABOUT MEDICINES [Questions from Smith, 2012
[8]
, based on the Beliefs about 
medicines questionnaire (BMQ) Horne, Weinman, Hankins, (1999) Psychology and Health, 14, 1-24]  
1 Using the scale below, please indicate the extent to 
which you agree or disagree with the following 
statements: 
1. Doctors use too many medicines  
2. People who take medicines should stop their 
treatment for a while every now and again 
3. Most medicines are addictive  
4. Natural remedies are safer than medicines  
5. Medicines do more harm than good  
6. All medicines are poisons 
7. Doctors place too much trust on medicines  
8. If doctors had more time with patients they 










G. ALLERGIES KNOWLEDGE & BELIEFS [Questions derived from the recent literature of the 
knowledge, attitude and practice [KAP] questions in AR and asthma, e.g. Alreshidi, 2017;Rajasekaran, 
2018 and Zhao, 2013 [9-11] 
 
1 Using the scale below, please indicate the extent to 
which you agree or disagree with the following 
statements: 





Strongly disagree  
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2. Hayfever/allergic rhinitis is caused by a virus 
3. Hayfever/allergic rhinitis can be prevented 
4. Hayfever/allergic rhinitis is linked to asthma 
and conjunctivitis 
5. Hayfever/allergic rhinitis runs in families  
6. Having Hayfever/allergic rhinitis can 
significantly impact on a person’s well-being 
7. Hayfever/allergic rhinitis can only be caused 
by a reaction to something in the air outdoors  
8. Hayfever/allergic rhinitis can only be 




<<CASE CHILDREN ONLY FROM HERE>> 





 Now thinking specifically about your [AGE AND 
GENDER OF CHILD; e.g. son aged 12 years] 
 Applies only 
if >1 eligible 
child 
1 In a typical week, on how many days is your child 
affected by their hayfever/allergic rhinitis (nasal and/or 
eye allergy)? 
1-3 days a week 
4 or more days a week 
 
2 In a typical month, how many weeks is your child 
affected by their hayfever/allergic rhinitis (nasal and/or 
eye allergy)? 
1-3 weeks  
Every week  
 
3 Does your child’s hayfever/allergic rhinitis (nasal 
and/or eye allergy): 
o Disturb their sleep 
o Restrict their daily activities like sports and 
leisure 
o Restrict their participation in school  
Is your child’s hayfever/allergic rhinitis (nasal and/or 









All no = 
mild; 1 or 




I CONTROL OF AR [based on recent symptom control]  
1 Using the scale below, and thinking about the last 2 
weeks, overall how bothersome have your child’s 




VAS SCALE: 0-10 cm  
0 cm = not at all bothersome 
10 cm = extremely bothersome (as bad as they can get) 
 A cut off of 











J. AR SYMPTOMS [Based on 
[12, 13, 15]





1 When your child has hayfever/allergic 
rhinitis (nasal and/or eye allergy), which of 
these symptoms does your child have?  
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2 Using the scale below, how bothersome 
are your child’s hayfever/allergic rhinitis 
(nasal and/or eye allergy) symptoms? 
 
 
VAS SCALE: 0-10 cm  
0 cm = not at all bothersome 
10 cm = extremely bothersome (as bad as 































selected at Q 
J1] 






3 What is the most bothersome 
hayfever/allergic rhinitis (nasal and/or eye 
allergy) symptom that your child seeks 






















selected at Q 
J1] 
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Irritable 
Easily distracted 







4 Which of the following words, if any, 
describe how your child feels when 
suffering from hayfever/allergic rhinitis 
(nasal and/or eye allergy) symptoms? 













Unable to perform at his or her best 
Less confident 
Indifferent/don’t care 
None of these 
 
5 During what time of the day are your 
child’s hayfever/allergic rhinitis (nasal 









be possible for 
all, but not for 
“no time is 
worse” 
6 Using the scale below, how much do your 
child’s hayfever/allergic rhinitis (nasal 
and/or eye allergy) symptoms interfere 
with each of the following: 
 
VAS SCALE: 0-10 cm  




Participation at school 
 
 
K. AR DIAGNOSIS [Questions in Meltzer, 2017
[4]
, and some questions developed based on 
information in Baena-Cagnani, 2015
[16]
 
1 How old was your child when he/she first started 
having these hayfever/allergic rhinitis (nasal and/or eye 
allergy) symptoms?  
  
2 Who made the diagnosis of hayfever/allergic rhinitis 
(nasal and/or eye allergy)? (Please select all that apply) 
General Practitioner  
Allergy specialist 
Clinical immunologist 
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3 Which, if any, of the following providers have you 
seen about your child’s hayfever/allergic rhinitis (nasal 
and/or eye allergy) symptoms? (Please select all that 
apply) 
General Practitioner  
Allergy specialist 
Clinical immunologist 











4 Who else have you sought advice from about your 
child’s hayfever/allergic rhinitis (nasal and/or eye 








5 What types of information have you received from a 
healthcare provider (specialist, doctor, pharmacist) 
about your hayfever/allergic rhinitis (nasal and/or eye 









Medicine side effects 
How to administer 
treatments 











Medicine side effects 
How to administer 
treatments 





6 Using the scale below, do you think you would benefit 
from more information on what hayfever/allergic 
rhinitis (nasal and/or eye allergy) is and how it is 
managed? 
0 = not at all 
1 = a little bit 
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3 = it would be very useful 
 
L. AR TRIGGERS & TESTING [Questions in Meltzer, 2017
[4]
 and some questions developed based 
on information in Zicari, 2013 
[2]
] 
1 Has your child ever been given a skin test to see what 
he/she was allergic to? 
Yes/no  
2 If yes, who carried out this skin test?  
 
General Practitioner  
Allergy specialist 
Clinical immunologist 








3 Has your child ever been given a blood test to see what 
he/she was allergic to?  
Yes/no  
4 If yes, who carried out this blood test?  
 
General Practitioner  
Allergy specialist 
Clinical Immunologist 








5 What kinds of things trigger your child’s 
hayfever/allergic rhinitis (nasal and/or eye allergy) 





House dust mites 
Animal dander (e.g. 
dead skin cells and 
hair or feathers) 
Foods 
Other allergens 
Do not know 
 
 





1A Which of the following types(s) of allergy 
medicines has your child ever tried using to 
manage his/her hayfever/allergic rhinitis (nasal 









1B Which of the following allergy medicines has your 
child ever tried using to manage his/her 
hayfever/allergic rhinitis (nasal and/or eye allergy) 
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Antihistamine nasal sprays  
Decongestants nasal sprays 
Corticosteroid nasal sprays 
Combination nasal sprays  
Anticholinergic nasal spray  
Intranasal mast cell 
stabilisers 
Nasal saline spray 
 
Eye drops: 
Antihistamine eye drops 












brands to aid 
with 
recognition, 




2A Which of the following types(s) of allergy 
medicines is your child currently using to manage 
his/her hayfever/allergic rhinitis (nasal and/or eye 








2B Which of the following allergy medicines is your 
child currently using to manage his/her 
hayfever/allergic rhinitis (nasal and/or eye allergy) 













Antihistamine nasal sprays  
Decongestants nasal sprays 
Corticosteroid nasal sprays 
Combination nasal sprays  
Anticholinergic nasal spray  
Intranasal mast cell 
stabilisers 
Nasal saline spray 
 
Eye drops: 
Antihistamine eye drops 












brands to aid 
with 
recognition, 
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3 Does your child ever need to use more than one 
type of medicine at the same time?  
 











4 Using the scale below, how bothersome would you 
say each of the following hayfever/allergic rhinitis 
(nasal and/or eye allergy) symptoms is when your 
child has NOT taken his/her allergy medication? 
 
VAS SCALE: 0-10 cm  














































5 Thinking about the medication(s) that your child 
currently uses to relieve his/her hayfever/allergic 
rhinitis (nasal and/or eye allergy) symptoms, who 








Family or friend 
 
 
6 Using the scale below, please indicate the extent to 
which you agree or disagree with the following 
statements: 
1. My child’s health at present depends on 
their allergy medicines 
2. My child having to take allergy 
medication worries me 
3. My child’s life would be impossible 
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4. Without his/her allergy medication my 
child would be very ill 
5. I sometimes worry about the long term 
effects of my child’s allergy medication 
6. My child’s allergy medication is mystery 
to me 
7. My child’s health in the future will 
depend on his/her allergy medication 
8. My child’s allergy medication disrupts 
his/her life 
9. I sometimes worry about my child 
becoming too dependent on his/her 
allergy medication 
My child’s allergy medication protects him/her 
from becoming worse 
7 Using the scale below and thinking about the 
medication(s) that your child currently uses to 
relieve his/her hayfever/allergic rhinitis (nasal 
and/or eye allergy) symptoms, how important is it 
to you that your child takes this medicine in the 




1 = not at all important 
2 = not very important 
3= somewhat important 







8 Thinking about the medication(s) that your child 
currently uses to relieve his/her hayfever/allergic 
rhinitis (nasal and/or eye allergy) symptoms, which 
statement best describes when they usually take 
their medication? (Please select only one answer 
for each medicine used) 
Takes it all year-round 
Takes it before the allergy 
season starts 
Takes it only during the 
allergy season 
Takes it only after 
symptoms have started 
Takes it only when 
symptoms are very 
bothersome 
Does not take it  
[Answer the 





using at Q 
M2. 
9 Thinking about the medication(s) that your child 
currently uses to relieve his/her hayfever/allergic 
rhinitis (nasal and/or eye allergy) symptoms, which 
statement best describes how often they take their 
medication? (Please select only one answer for 
each medicine used) 
Once a month 
Once a week 
Once a day 
Twice a day 
Three times a day 
Only when symptoms are 
present 
Only when symptoms are 
very bothersome 
Does not take it  
[Answer the 





using at Q 
M2. 
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11 Using the scale below, how bothersome are your 
child’s hayfever/allergic rhinitis (nasal and/or eye 
allergy) symptoms today?  
 
VAS SCALE: 0-10 cm  












• <20: well 
controlled.
[17] 
12 Using the scale below, how satisfied are you with 
the effectiveness of each of the following types of 
medication your child uses to relieve his/ 
hayfever/allergic rhinitis (nasal and/or eye allergy) 
symptoms?  
 
0 = does not use this medication 
1 = not at all satisfied 
2 = somewhat satisfied 
3= satisfied 
4 = very satisfied 













Antihistamine nasal sprays  
Decongestants nasal sprays 
Corticosteroid nasal sprays 
Combination nasal sprays  
Intranasal mast cell 
stabilisers 
Nasal saline spray 
 
Eye drops: 
Antihistamine eye drops 














using at Q 





them to select 
to aid with 
this] 
[IPSOS Please Note: For those children who are taking a Sanofi product AND who respond to the 
above question with options 1 or 2, this would be reportable to Sanofi Product Safety as PV Data 
(lack of efficacy)] 
13 Thinking about the medication(s) that your child 
currently uses to relieve his/her hayfever/allergic 
rhinitis (nasal and/or eye allergy) symptoms, how 
would you describe your child’s ability to always 
take that medicine in the exact way it is 













using at Q 
M2. 
Based on 
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self-rating 
scale item 
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Medicine descriptions for use for use at Q’s M1A and B, 2A and B, 8, 9, 11 and 12: 
 
Category Medicine type Active ingredient  Example of brand 
Tablets/liquids Oral non-sedating 
antihistamines 
• Cetirizine  
 
Little Allergies for Children, Alzene, Zilarex, Zyrtec, Zodac, 
ZepAllergy, Cetrelief 
  • Desloratadine  
 
Aerius 
  • Fexofenadine  
 
Allerfexo, Telfast, Amcal Fexo, Chemist’s Own Fexo, Fexal, 
Fexotabs, Guardian Fexo, Tefodine, Xergic, Pharmacy 
Action Fexorelief 
  • Levocetirizine 
 
Xyzal 
  • Loratadine 
 
Claratyne, Amcal Loratadine, Chemist’s Own loratadine, 
Guardian Loratadine, Alledine, Allerdyne, Allereze, Lorano 
 Oral sedating 
antihistamines 
• Cyproheptadine  Periactin 
  • Dexchlorpheniramine Polaramine 
  • Diphenhydramine Children's Paedamin Antihistamine 
  • Pheniramine Avil 
  • Promethazine Allersoothe, Phenergan 
 Oral decongestants • Pseudoephedrine  Sudafed 
 Oral corticosteroids • Prednisone Panfacort 
 Oral combination 
products 
• Pseudoephedrine + 
fexofenadine  
Telfast decongestant 
  • Pseudoephedrine + loratadine Claratyne-D 
 Leukotriene receptor 
antagonists 
• Montelukast  Singulair, Lukair 
  • Zafirlukast Accolate 
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Nasal sprays:    
 Antihistamine nasal 
sprays 
• Azelastine  Azep 
  • Levocabastine Livostin nasal spray 
 Decongestant nasal 
sprays 
• Oxymetazoline  Chemists’ Own Decongestant Nasal Spray, Demazin 12 Hour 
Relief Nasal Spray, Dimetapp 12 Hour Nasal Spray, Drixine, 
Logicin Rapid Relief Nasal Spray, Pharmacy Action Nasal 
decongestant Spray, Vicks Sinex 
  • Xylometazoline FLO Xylo-POS Nasal Spray, Otrivin Nasal Spray, Otrivin 
Junior, Otrivin Menthol, Otrivin Plus 
  • Tramazoline Spray-Tish Menthol, Spray-Tish 
 Corticosteroid nasal 
sprays 
• Beclomethasone  Beconase 
  • Budesonide Rhinocort Hayfever, Rhinocort, Budamax 
  • Ciclesonide Omnaris 
  • Fluticasone Avamys, Flixonase 
  • Mometasone Nasonex, Sensease Nasal Allergy Relief, Chemmart 
Mometasone Nasal Spray, Terry White Chemists 
Mometasone Nasal Spray, APO Mometasone Nasal Spray 
  • Triamcinolone Telnase 
 Combination nasal 
sprays 
• Azelastine + fluticasone  Dymista 
 Anticholinergic nasal 
spray 
• Ipatropium bromide  Atrovent Nasal 
 Intranasal mast cell 
stabilisers 
• Sodium cromoglycate  Rynacrom 
 Nasal saline spray • Sodium chloride  Fess, Flo, Flo Kids, PediaMist 
Eye drops:  • Sodium cromoglycate Cromolux eye drops, Opticrom eye drops 
  •  Lodoximide Lomide eye drops 
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  • Antazoline + naphazoline Albolon-A eye drops, Antistine-Privine eye drops 
  • Azelastine Eyezep eye drops 
  • Ketotifen Zaditen eye drops 
  • Levocabastine Livostin eye drops, Zyrtec Levocabastine eye drops 
  • Olopatadine Patanol 
Other:    
 Allergen immunotherapy  • Injections or “shots” given by a 
doctor 
 
 Vitamins • Vitamin C  
  • Vitamin C combination Garlic, Vitamin C and horseradish 
 Herbal supplements • Herbal combination  
• Quercetin/bioflavonoids 
• MSM (methylsulfonylmethane)  
• Glutamine 
• Bromelain 
• Curcumin (turmeric) 
• Probiotics 




Ki Hayfever Control Formula 
Sourced from:  
Smith P, Price D, Harvey R, et al. Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. Journal of Asthma and 
Allergy. 2017;10:153-161.  
http://www.mydr.com.au/allergy/hay-fever-treatments 
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Supplementary Tables 
Adequacy of symptom control drives health-related quality of life in paediatric allergic rhinitis: 
Insights from an Australian cross-sectional study 
Sinthia Bosnic-Anticevich, Peter Smith, Michael J. Abramson, Charlotte Hespe, Menai Johnson, 
Rodney Stosic, David Price 
 
Supplementary Table S1. Respondent demographics 




Controls (No AR) 
N=501 
Gender    
Male 528 (34.3%) 379 (36.4%) 149 (29.7%) 
Female 1013 (65.7%) 661 (63.6%) 352 (70.3%) 
Mean age (±SD), years  41.6 ± 9.0 41.4 ± 8.9 42.1 ± 9.1 
Family demographics    
Number of children aged 2-15    
1 718 (46.6%) 499 (48.0%) 219 (43.7%) 
2 621 (40.3%) 428 (41.2%) 193 (38.5%) 
3 156 (10.1%) 86 (8.3%) 70 (14.0%) 
4  38 (2.5%) 24 (2.3%) 14 (2.8%) 
5  8 (0.5%) 3 (0.3%) 5 (1.0%) 
Gender of children:    
Male 771 (50.0%) 536 (51.5%) 235 (46.9%) 
Female 770 (50.0%) 504 (48.5%) 266 (53.1%) 
Mean age of children, years 8.9 ± 4.3 9.4 ± 4.2 7.9 ± 4.3 
Geographic location    
Urban/capital city  1079 (70.0%) 777 (74.7%)* 302 (60.3%) 
Regional/Rural 462 (30.0%) 263 (25.3%) 199 (39.7%) 
Education    
Less than Year 12 or equivalent 146 (9.5%) 88 (8.5%) 58 (11.6%) 
Year 12 or equivalent (HSC/Leaving 
certificate) 
233 (15.2%) 158 (15.2%) 75 (15.0%) 
Vocational Qualification 409 (26.7%) 260 (25.0%) 149 (29.7%) 
Bachelor degree  555 (36.2%) 382 (36.7%)† 173 (34.5%) 
Masters degree 163 (10.6%) 130 (12.5%)† 33 (6.6%) 
Doctorate 27 (1.8%) 17 (1.6%)† 10 (2.0%) 
Not specified  8 (0.5%) 5 (0.5%) 3 (0.6%) 
Pre-tax household income    
Up to $49,999  264 (17.1%) 163 (15.7%) 101 (20.2%) 
$50,000-$74,999  269 (17.5%) 192 (18.5%) 77 (15.4%) 
$75,000-$99,999  294 (19.1%) 206 (19.8%) 88 (17.6%) 
Over $100,000 600 (38.9%) 424 (40.8%) 176 (35.1%) 
Not specified  114 (7.4%) 55 (5.3%) 59 (11.8%) 
Note: The survey recruited consecutive, self-identified panel respondents until quotas were met. The quotas were 
stratified based on the age and gender of the child, and geographical location. 
* Statistically significant association between location and presence of AR: higher in urban areas (P<0.0001);  
† When higher education levels are combined, statistically significant association between education and presence 
of AR: higher in more educated participants (p<0.005), which may be a reflection of better recognition and/or 
access to medical care.   
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Supplementary Table S2.  Symptoms experienced by children with AR. 
Children aged 6-15 years 
  Cases (AR) Cases (AR) 
Cases (AR) Treated Not treated 
N= 797 N= 730 N=67 
Nasal symptoms:       
Runny nose 63%         66% 37%  
Repeated sneezing 55%         56% 42%  
Itchy nose 49%         51% 25%  
Nasal congestion 43%         45% 24%  
Eye symptoms:       
Itchy eyes 59%         62% 33%  
Watering eyes 49%         51% 27%  
Red eyes 30%         32% 7%  
Bronchial/upper airway 
symptoms:   
    
Dry cough 30%         30% 30% 
Snoring 22%         22% 15% 
Other:       
Irritable 34%         35% 19%  
Disturbed sleep 30%         32% 10%  
Difficulty getting to sleep 25%         26% 6%  
Headaches/sinus pain 26%         27% 18% 
Easily distracted 16%         17% 12% 
Ear pain 12%         12% 7% 
Facial pain 8%         8% 4% 
Difficulty hearing 6%         6% 7% 
Green shading indicates a significant difference between respective AR Treated and AR Not Treated groups at 
95% CI (p<0.05).  
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Supplementary Table S3.  Overall usage trends for different classes of 
medications* (most common time to use is highlighted). 
Cases (AR) Treated 
N= 939* N 





























2% 7% 30% 31% 30% 
Oral decongestants 77 
(8.2%) 




















9% 8% 25% 38% 21% 
Nasal saline spray 114 
(12.2%) 





3% 3% 37% 43% 14% 
Other eye drops 30 
(3.2%) 
0% 4% 27% 47% 23% 
*More than one medicine category could be chosen per child. 
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